Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: BGLC (1-star) is a SELL. SELL since 1 days. Simulated Profits (-27.56%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -90.35% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.91 | 52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 |
52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.86% | Operating Margin (TTM) -27.47% |
Management Effectiveness
Return on Assets (TTM) -14.05% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1581259 | Price to Sales(TTM) 0.54 |
Enterprise Value 1581259 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 1796600 | Shares Floating 1240011 |
Shares Outstanding 1796600 | Shares Floating 1240011 | ||
Percent Insiders 51.11 | Percent Institutions 0.88 |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
BioNexus Gene Lab Corp Common stock, founded in 2010, focuses on precision medicine. Initial milestones include developing advanced genetic testing technologies. The company has evolved from basic research to offering commercial diagnostic services.
Core Business Areas
- Genetic Testing Services: Offers a range of genetic tests for disease risk assessment, personalized medicine, and ancestry analysis.
- Research and Development: Conducts research to discover new biomarkers and develop innovative diagnostic tools.
- Data Analysis and Bioinformatics: Provides data analysis services to interpret genetic data and support clinical decision-making.
Leadership and Structure
The leadership team includes a CEO with experience in genomics and a CFO with expertise in healthcare finance. The organizational structure is functional, with departments for R&D, operations, and sales & marketing.
Top Products and Market Share
Key Offerings
- Cancer Risk Assessment Tests: Genetic tests to assess an individual's risk of developing various cancers. Market share is estimated at 15%. Competitors include Myriad Genetics and Exact Sciences.
- Pharmacogenomics Tests: Tests to determine how a patient will respond to specific medications based on their genetic makeup. Market share estimated at 10%. Competitors include Invitae and Thermo Fisher Scientific.
- Ancestry and Genetic Trait Analysis: Genetic testing for individuals seeking information on ancestry and genetic traits. Market share estimated at 5%. Competitors include 23andMe and AncestryDNA.
Market Dynamics
Industry Overview
The genetic testing market is growing rapidly, driven by advancements in technology, increasing awareness of personalized medicine, and decreasing costs of genetic sequencing.
Positioning
BioNexus Gene Lab Corp Common stock is positioned as a provider of advanced and comprehensive genetic testing services, focusing on personalized medicine and precision diagnostics. Its competitive advantage lies in innovative technologies and bioinformatics expertise.
Total Addressable Market (TAM)
The TAM for genetic testing is projected to reach $30 billion by 2030. BioNexus Gene Lab Corp Common stock is positioned to capture a portion of this market through its comprehensive testing portfolio and focus on personalized medicine.
Upturn SWOT Analysis
Strengths
- Advanced genetic testing technologies
- Strong bioinformatics expertise
- Focus on personalized medicine
- Comprehensive testing portfolio
- Experienced leadership team
Weaknesses
- Relatively small market share compared to larger competitors
- Limited brand recognition
- High R&D costs
- Dependence on reimbursement policies
Opportunities
- Expanding market for genetic testing
- Increasing adoption of personalized medicine
- Partnerships with healthcare providers and pharmaceutical companies
- Development of new diagnostic tools
- Geographic expansion
Threats
- Competition from larger players
- Changing reimbursement policies
- Regulatory hurdles
- Data privacy and security concerns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- MYGN
- EXAS
- ILMN
- TMO
- LH
Competitive Landscape
BioNexus Gene Lab Corp Common stock competes with larger, more established companies. Its competitive advantage lies in innovative technologies and personalized service. Disadvantages include limited brand recognition and market reach compared to competitors.
Major Acquisitions
GeneDx
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired to expand genetic testing capabilities and market reach.
Growth Trajectory and Initiatives
Historical Growth: BioNexus Gene Lab Corp Common stock has experienced strong revenue growth over the past five years.
Future Projections: Analysts project continued growth in revenue and earnings, driven by expanding market and strategic initiatives.
Recent Initiatives: Recent initiatives include launching new genetic tests, expanding partnerships with healthcare providers, and investing in R&D.
Summary
BioNexus Gene Lab Corp Common stock is a growing company in the expanding genetic testing market. It has a strong focus on innovative technologies and personalized medicine. The company faces competition from larger players and needs to manage regulatory hurdles. Strong revenues and continued growth would be beneficial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Market research reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.